Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma.


Journal

Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169

Informations de publication

Date de publication:
03 Apr 2021
Historique:
pubmed: 20 5 2021
medline: 22 1 2022
entrez: 19 5 2021
Statut: ppublish

Résumé

To provide recommendations for diagnosis of vitreoretinal lymphoma (VRL). Literature was reviewed for reports supporting the diagnosis of VRL. A questionnaire (Delphi 1 round) was distributed to 28 participants. In the second round (Delphi 2), items of the questionnaire not reaching consensus (75% agreement) were discussed to finalize the recommendations. Presenting symptoms include floaters and painless loss of vision, vitreous cells organized into sheets or clumps. Retinal lesions are usually multifocal creamy/white in the outer retina. Other findings include retinal lesions with "leopard-skin" appearance and retinal pigment epithelium atrophy. Severe vitreous infiltration without macular edema is the most likely presentation. Diagnostic vitrectomy should be performed. Systemic corticosteroid should be discontinued at least 2 weeks before surgery. An interleukin (IL)-10:IL-6 ratio > 1, positive mutation for the myeloid differentiation primary response 88 gene and monoclonality are indicators of VRL. Multi-modal imaging (optical coherence tomography, fundus autofluorescence) are recommended. A consensus meeting allowed the establishment of recommendations important for the diagnosis of VRL.

Identifiants

pubmed: 34009095
doi: 10.1080/09273948.2021.1878233
doi:

Substances chimiques

Biomarkers, Tumor 0
IL10 protein, human 0
IL6 protein, human 0
Interleukin-6 0
MYD88 protein, human 0
Myeloid Differentiation Factor 88 0
Interleukin-10 130068-27-8

Types de publication

Consensus Development Conference Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

507-520

Auteurs

Denise Carbonell (D)

Ocular Inflammation and Immunology section, Singapore National Eye Centre, Singapore.

Sarakshi Mahajan (S)

St. Joseph Mercy Oakland, Pontiac, Michigan , United States.

Soon-Phaik Chee (SP)

Ocular Inflammation and Immunology section, Singapore National Eye Centre, Singapore.
Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Singapore Eye Research Institute, The Academia, Singapore.
Department of Ophthalmology & Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore.

Bianka Sobolewska (B)

Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany.

Rupesh Agrawal (R)

Department of Ophthalmology, National Healthcare Group Eye Institute, Singapore.

Tanja Bülow (T)

Department of Medical Statistics, RWTH Aachen University, Aachen, Germany.

Vishali Gupta (V)

Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Nicholas P Jones (NP)

Uveitis service, Manchester Royal Eye Hospital, Manchester; Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Massimo Accorinti (M)

Department of Ophthalmology, Sapienza University of Rome, Rome, Italy.

Tracy Batchelor (T)

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts , United States.

Jyotirmay Biswas (J)

Uveitis & Cornea Services, Sankara Nethralaya, Chennai, India.

Luca Cimino (L)

Ocular Immunology Unit, Azienda USL-IRCCS, Di Reggio Emilia, Italy.

Ninette H tenDam-van Loon (NH)

Department of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands.

Alejandra de-la-Torre (A)

NeURos Research Group, Escuela De Medicina Y Ciencias De La Salud, Universidad Del Rosario, Bogotá, Colombia.

Shahar Frenkel (S)

Department Division of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Jacob Pe'er (J)

Department Division of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Michal Kramer (M)

Uveitis service, Department of Ophthamology, Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.

Elisabetta Miserocchi (E)

Ocular Immunology and Uveitis Service, University Hospital San Raffaele Milan, Milan, Italy.

Manabu Mochizuki (M)

Department of Ophthalmology & Visual Science Tokyo Medical and Dental University Graduate School, Miyata Eye Hospital, Miyakonojo, Miyazaki, Japan.

Thomas Ness (T)

Department of Ophthalmology, University Eye Clinic Freiburg, Freiburg, Germany.

James T Rosenbaum (JT)

Uveitis Section, Oregon Health & Science and University Casey Eye Institute, Portland, Oregon, USA.

H Nida Sen (HN)

Uveitis Clinic, National Eye Institute, Bethesda, Maryland, USA.

Michael Simion (M)

Tel Aviv, Israel.

Helmut Sitter (H)

Institute of Surgical Research, Dept. Of Medicine, Philipps-University Marburg, Marburg, Germany.

Daniel V Vasconcelos-Santos (DV)

Department of Ophthalmology, Uveitis section, Universidade Federal De Minas Gerais, Belo Horizonte, Brazil.

Zohar Habot-Wilner (Z)

Division of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.

Sarah E Coupland (SE)

Pathology Department, Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.

José S Pulido (JS)

Departments of Ophthalmology and Molecular Medicine, Mayo Clinic, Philadelphia, Pennsylvania, USA.

Justine Smith (J)

Eye and Vision Health section, Flinders University College of Medicine and Public Health, Adelaide, Australia.

Jennifer E Thorne (JE)

Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.

Manfred Zierhut (M)

Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany.
Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH